Heartwire
Late-Breaking Clinical Trials I
ACC/i2 Joint Session
Dimanche 3 avril 2011, 8 h 00 – 10 h 00
Ernest N Morial Convention Center, Joint Main Tent: La Nouvelle
ACC/i2 Joint Session
Dimanche 3 avril 2011, 8 h 00 – 10 h 00
Ernest N Morial Convention Center, Joint Main Tent: La Nouvelle
Télécharger le PDF  |
Transcatheter Aortic Valve Implantation versus Surgical Aortic Valve Replacement in "High Risk" Patients with Aortic Stenosis: The Randomized PARTNER Craig R Smith, Columbia University, New York, É.-U. 9 h 13 – 9 h 25 |
| Lifetime Cost Effectiveness of Transcatheter Aortic Valve Implantation Compared with Standard Care among Inoperable Patients with Severe Aortic Stenosis: Results from the Randomized PARTNER Trial (Cohort B) Matthew R Reynolds, Beth Israel Deaconess Medical Center, Boston, É.-U. 9 h 25 – 9 h 37 |
|
| Discussion 9 h 37 – 9 h 52 |
Late-Breaking Clinical Trials II
ACC/i2 Joint Session
Lundi 4 avril 2011, 8 h 00 – 9 h 30
Ernest N Morial Convention Center, Joint Main Tent: La Nouvelle
ACC/i2 Joint Session
Lundi 4 avril 2011, 8 h 00 – 9 h 30
Ernest N Morial Convention Center, Joint Main Tent: La Nouvelle
|
Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using
Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease
(PRECOMBAT) trial Seung-Jung Park, Asan Medical Center, Séoul, Corée du Sud 8 h 00 – 8 h 17 (présentation et débat d’experts) |
| EVEREST II Randomized Clinical Trial: Two Year Outcomes Ted Feldman, Evanston Northwestern Healthcare, Evanston, É.-U. 8 h 17 – 8 h 34 (présentation et débat d’experts) |
|
| Medical Therapy with or without Coronary Artery Bypass Graft Surgery in Patients with Ischemic Cardiomyopathy: Results of the Surgical Treatment of Ischemic Heart Failure Trial Eric J Velazquez, Duke University, Durham, É.-U. 8 h 34 – 8 h 51 (présentation et débat d’experts) ) |
|
| Influence of Myocardial Viability on Outcome of Patients with Coronary Artery Disease and Left Ventricular Function Undergoing Medical Therapy with and without Surgical Revascularization: Results of the Surgical Treatment for Ischemic Heart Failure Trial Robert O Bonow, Northwestern University Medical School, Chicago, É.-U. 8 h 51 – 9 h 08 (présentation et débat d’experts) |
|
| Radial Artery and Saphenous Vein Patency More than Five Years Following Coronary
Artery Bypass Surgery: Results from the Randomized Multicentre Radial Artery Patency Study (RAPS) Stephen E Fremes, Sunnybrook Health Sciences Centre, Toronto, Canada 9 h 08 – 9 h 25 (présentation et débat d’experts) |
Late-Breaking Clinical Trials III: Interventional Cardiology
ACC/i2 Joint Session
Lundi 4 avril 2011, 10 h 45 – 12 h 15
Ernest N Morial Convention Center, Joint Main Tent: La Nouvelle
ACC/i2 Joint Session
Lundi 4 avril 2011, 10 h 45 – 12 h 15
Ernest N Morial Convention Center, Joint Main Tent: La Nouvelle
|
Long-Term Outcomes after Use of Drug-Eluting Stents and Bare Metal Stents for the Treatment of Saphenous Vein Graft Lesions: Results of the Randomized ISAR-CABG Trial Julinda Mehilli, Deutsches Herzzentrum, Munich, Allemagne 10 h 45 – 11 h 03 (présentation et débat d’experts) |
| Rival Trial: A Randomized Comparison of Radial versus Femoral Access for Coronary Angiography or Intervention in Patients with Acute Coronary Syndromes Sanjit S Jolly, Population Health Research Institute, McMaster University, Hamilton Health Sciences, Hamilton, Canada 11 h 03 – 11 h 21 (présentation et débat d’experts) |
|
| One Year Clinical Outcomes from the Pivotal Multicenter RESOLUTE US Study Martin B Leon, Columbia University Medical Center, New York, É.-U. 11 h 21 – 11 h 39 (présentation et débat d’experts) |
|
| A Prospective, Randomized, Investigation of a Novel Platinum Chromium Everolimus-Eluting Coronary Stent: The PLATINUM Trial Gregg W Stone, Columbia University Medical Center and the Cardiovascular Research Foundation, New York, É.-U. 11 h 39 – 11 h 57 (présentation et débat d’experts) |
|
| Renal Insufficiency Following Contrast Media Administration Trial Ii (REMEDIAL II): Renalguard System In High-risk Patients For Contrast-induced Acute Kidney Injury Carlo Briguori, Clinica Mediterranea, Naples, Italie 11 h 57 – 12 h 15 (présentation et débat d’experts) |
Late-Breaking Clinical Trials IV
ACC/i2 Joint Session
Mardi 5 avril 2011, 8 h 00 – 9 h 30
Ernest N Morial Convention Center, Joint Main Tent: La Nouvelle
ACC/i2 Joint Session
Mardi 5 avril 2011, 8 h 00 – 9 h 30
Ernest N Morial Convention Center, Joint Main Tent: La Nouvelle
|
Rivaroxaban Compared with Enoxaparin for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients Alexander Cohen, Bayer HealthCare AG, Leverkusen, Allemagne 8 h 00 – 8 h 17 (présentation et débat d’experts) |
| The Comparison of High-dose Angiotensin II Receptor Blocker (ARB) Monotherapy Versus Combination Therapy of ARB with Calcium Channel Blocker on Cardiovascular Events in Japanese Elderly High-Risk Hypertensive Patients: Olmesartan and Calcium Antagonists Randomized (OSCAR) Study Hisao Ogawa, Kumamoto University, Kumamoto, Japon 8 h 17 – 8 h 34 (présentation et débat d’experts) |
|
| Comparison between Valsartan and Amlodipine Regarding Cardiovascular Morbidity and Mortality in Hypertensive Patients with Glucose Intolerance (NAGOYA HEART Study) Toyoaki Murohara, Nagoya University School of Medicine, Nagoya, Japon 8 h 34 – 8 h 51 (présentation et débat d’experts) |
|
| Selective Inhibition of Delta Protein Kinase C to Reduce Infarct Size after Primary
Percutaneous Intervention for Acute Myocardial Infarction: The PROTECTION-AMI
Phase IIb Clinical Trial A Michael Lincoff, Cleveland Clinic, Cleveland, É.-U. 8 h 51 – 9 h 08 (présentation et débat d’experts) |
|
| The Randomized Comparison of Six-Month versus 12-Month Duration of Dual Antiplatelet Therapy after Implantation of Drug Eluting Stent: From Comparison of Everolimusversus Sirolimus-Eluting Stents for Coronary Revascularization (EXCELLENT) Trial Hyeon-Cheol Gwon, Samsung Medical Center, Séoul, Corée du Sud 9 h 08 – 9 h 25 (présentation et débat d’experts) |
